Prostate Cancer Care Disparity Analysis Project (ProGAP)
Launched by ANKARA UNIVERSITY · Sep 21, 2024
Trial Information
Current as of April 02, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Prostate cancer stands as one of the most common cancers among men worldwide, with outcomes and care quality significantly varying due to a multitude of factors including geographic location, healthcare infrastructure, socioeconomic status, and clinical practices. The ProGAP project is conceived to delve into these variations, providing a detailed examination of the global landscape of prostate cancer care.
Objectives:
1. To systematically gather and analyze data on current diagnostic methods, treatment modalities, and management practices for prostate cancer from a wide range of countrie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Urologists, Uro-oncologists, Medical oncologists, Radiation oncologists
- Exclusion Criteria:
- • Non-clinical healthcare professionals Healthcare professionals not directly involved in the care of prostate cancer patients, Healthcare professionals with missing or incorrect email addresses
Trial Officials
Yüksel Ürün
Study Director
Ankara University
Deborah Mukherji
Study Director
Clemenceau Medical Center Hospital Dubai
Mohammed Shahait
Study Director
Al Zahra Hospital Dubai
Luis Castelo Branco
Study Director
IOSI Oncologist Institute of Southern Switzerland
About Ankara University
Ankara University, a prominent institution in Turkey, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a strong emphasis on scientific rigor and ethical standards, the university collaborates with various stakeholders to design and implement studies that address critical health challenges. Leveraging a diverse network of experienced researchers and state-of-the-art facilities, Ankara University aims to contribute significantly to the global medical community by generating valuable insights and fostering the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported